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Doxepin Hydrochloride is an anti-
depressant which though widely used abroad, 
is relatively new on the Indian scene. 
Chemically, Doxepin, is N, N-Dimethyl-
dibenz (b, e) oxepin- ii(6H) propylamine 
hydrochloride (Krakowsi, 1968). Doxepin, 
being a tricyclic compound, has its basic 
action similar to other compounds of the 
group (Groton, 1967). It is tertiary 
amine like Amitriptyline and Imipramine 
which confers mood improving properties 
on the compound (Arieti, 1975). Some 
workers have rated it as good or slightly 
superior to Imipramine and Amitriptyline 
whereas Swiss Psychiatrists have not found 
it so. (Frank, 1969). 
In India few research workers have 
used Doxepin to compare its effect in Anxiety 
neurosis with Trifluoperazine (Kishore et 
al., 1973), or to determine an optimum 
dose of the drug in patients suffering from 
anxiety state associated with depression 
(D'Souza, 1978) or to compare its effec-
tiveness with Placebo (Vahia et al., 1974). 
Recently, it has been reported by 
some workers that steady-state levels of a 
tricyclic antidepressant can be maintained 
by administering the drug as a single dose 
at night (Kramer, 1962, Dimascio et al., 
1969, Marshall, 1971) and clinical ex-
perience suggests that this method of adminis-
tration is effective in relieving symptoms 
of depression. 
MATERIAL AND METHOD 
The study was conducted at the De-
partment of Psychiatry and Human Be-
1 Professor and Head, | Department of Ps 
•Resident, f Panaji,—Goa, « 
.P.M., F.R.C. Psych. (Lond.) F.A.P.A. 
haviour, Goa Medical College, Panaji-Goa. 
In this double-blind trial, 43 patients 
suffering from depression as a primary 
illness, and in whom treatment with anti-
depressants was thought suitable, were selec-
ted. Diagnosis of depression was made 
by two qualified psychiatrists independent 
of each other. The duration of depression 
varied from 15 days to 36 months with a 
mean of 5.7 months. Patients receiving 
previous therapy were given a drug-free 
wash out period of miniumm 10 days. 
The minimum score (on Hamilton De-
pressive Rating Scale) for inclusion into the 
trial was 30. The duration of the trial 
was four weeks. Routine haematological 
studies, liver function tests and fasting 
blood sugar determinations were done in 
all patients. 
The patients admitted into the trial 
were randomly allocated to either group D 
(three times daily dose) or Group N, (single 
nocturnal dose) and there was no attempt 
to make the two sexes equal in the sampling. 
The group receving three times daily dose 
of doxepin (25 mg) was given equal, total 
number of placebo capsules as a single dose 
(75 mg) at night and the group receiving 
single dose of doxepin at night received 
identical placebo capsules three times daily 
in order to ensure that the trial remained 
strictly double blind. 
Initially, in the first week, patients 
belonging to group D received one capsule 
of doxepin three times daily and patients in 
Group N were given single nocturnal 
dose of three doxepin capsules. Thereafter, 
ychiatry and Human Behaviour, Goa Medical College, 
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depending on the patient's response, dose 
was increased every week, the maximum 
number of doxepin capsules being six (150 
mg) daily. To every change in the day-
time dose there was a corresponding change 
in the number of capsules given as a single 
dose at night and vice versa. Doxepin 
and placebos were supplied in identical 
looking capsules containing 25 mg. of the 
active or the inert agent. Capsules for 
daytime use were dispensed in white bottles 
and for use at night in amber coloured 
bottles so as to avoid confusion in dis-
pensing. 
Assessment was done on Hamilton 
Rating Scale before treatment and at the 
end of 1st, 2nd, 3rd and 4th week of treat-
ment. At each interview, physiological 
concomitants like bodyweight, pulse rate 
and blood pressure in supine and standing 
positions were measured and side effects 
noted. Out of 43 patients 11 patients 
occasionally needed supportive treatment 
with diazepam to control insomnia. The 
patients were considered to have their 
symptoms cleared when the final score on 
Hamilton rating scale dropped to the range 
of 0 to 5, marked improvement 6 to 15, 
moderate improvement 16 to 25, slight im-
provement 26 to 29, no change when range 
remained between 30 and above and worse 
when it exceeded the pretreatment score. 
RESULTS 
Of the 43 patients enrolled in the study, 
5 were dropped from the study in the first 
week due to their non-co-operation. Other-
wise there was not a single case of drop out 
due to side-effects of the drug itself. Out 
of die remaining 38 patients 21 belonged 
to group D (Day) and 17 to group N 
(Night). 
Table I shows profile of the two groups. 
No significant difference between groups 
N and D was found in terms of age, sex, 
pretreatment mean Hamilton score, number 
of attacks of depression and the numbers 
TABLE I—Profile of patients 
Group D Group N 
(drug during (during ni-
day) ght) 
No. of Patients 
Sex— Male 
Female 
Age— Range 
Mean 
No. of attacks of depre-
ssion 
Range 
Mean 
21 
7 
14 
28-66 years 
39.43 years 
1—8 
2.3 
•Mean Pre-treatment Hamil- 35.33 
ton score. 
No. of patients who recei-
ved previous therapy  12 
17 
7 
10 
35-56 years 
39.18 years 
1—15 
2.5 
32.76 
12 
t=0.72, d.f. = 36, N.S. 
that received previous treatment. Both 
the regimens were effective in reducing 
Hamilton score. 
Table II shows degree of response to 
the individual symptoms in both the groups 
of drug therapy. The effect of nocturnal 
dose (Group N series) on the target symp-
toms of depression, anxiety and insomnia 
was quite impressive. Nevertheless, the 
difference in the amelioration of symptoms 
between group N and D series did not 
reach statistical significance. 
Table III shows results of the Clinician's 
overall assessment. In Group D, 5 showed 
symptoms cleared, 12 showed marked im-
provement, 3 showed moderate improve-
ment and one no change. 
In group N, 6 were cleared of their 
symptoms, marked improvement was seen 
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TABLE II—Degree of response to the individual symptoms in both the groups of drug therapy 
Thrice daily dose  Single Nocturnal dose 
Symptoms 
Total 
21 
20 
21 
7 
16 
14 
19 
9 
Responded 
18 
17 
13 
7 
14 
5 
6 
4 
(85.7%) 
(85%) 
(61.9%) 
(100%) 
(87.5%) 
(35.7%) 
(31.6%) 
(44.4%) 
Total 
16 
17 
17 
8 
12 
10 
16 
2 
Responded 
1 (94.1%) 
15 (88.2%) 
14 (82.4%) 
8 (100%) 
12 (100%) 
4 (40%) 
6 (37.5%) 
2 (100%) 
Depression 
Anxiety 
Insomnia 
Agitation 
Retardation 
Hypochondriasis 
Somatic symptoms 
Obsessional symptoms 
TABLE III—Global clinical improvement based 
on reduction in M. H. R. scale 
Total Hamilton score at the end Group D Group N 
of 4th week (N=21) (N=17) 
TABLE IV—Side effects 
0—5 (symptoms cleared) 
6—15 (marked improvement) 
16—25 (Moderate improvement) 
26—29 (slight improvement) 
30—-Original score (no change) 
More than original score 
(work). 
12 
3 
10 
1 
either group became worse with treat-
ment. 
Table IV shows incidence of side-effects. 
Side-effects reported were mild and did not 
require discontinuation of medication. 
It was noteworthy that in group N, 
there was no incidence of side-effects like 
palpitation, nausea, vomiting or blurred 
vision. 
Table V shows the increase in body 
weight in both groups. In group D, the 
gain in weight was between 0.5 to 3.5 kg. 
Dryness of mouth 
Palpitations 
Dizziness 
Constipation 
Fatigue 
Tachycardia 
Sweating 
Drowsiness 
Vomiting 
Nausea 
Mild excitement 
Blurred vision 
•Mild urinary reten-
tion 
Tremor 
Number of p 
Group D 
(drug during 
day) 
(N=21) 
17 (81.0) 
6 (28.6) 
6 (28.6) 
5 (23.8) 
3 (14.3) 
2 (9.5) 
3 (14.3) 
1 (4.8) 
2 (9.5) 
1 (4.8) 
2 (9.5) 
2 (9.5) 
1 (4.8) 
1 (4.8) 
Orthostatic hypotension 
Total number of side-
effects. 
52 
atients 
Group N 
(drug at 
night) 
(N = 17) 
J4 (82.4) 
5 (29.4) 
5 (29.4) 
2 (11.8) 
3 (17.6) 
4 (23.5) 
3 (17.6) 
1 (5.9) 
4 ((23.5) 
41 
Figures in parenthesis indicate percentage. 
•This refers to a patient who developed mild urinary 
retention, after the second week of therapy. With 
additional symptomatic treatment the condition was 
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TABLE V—Gain in body weight 
Group D 
(N=21 pts.) 
Group N 
(N=17 pts.) 
Increase in weight in Kgs. 
in 4 weeks 
Range (Kgs) Mean (Kgs) 
1.43 0.5 to 3.5 
1.75 0.5 to 3.0 
in 4 weeks, with a mean of 1.43 kg. In 
group N, weight gain was in the range 
of 0.5 to 3.0 kg. with a mean of 1.75 kg. 
DISCUSSION 
On analysis of data, it was observed 
that of 38 patients who completed the 
trial, in 11 the symptoms were cleared, 22 
showed marked improvement, 4 moderate 
improvement, 1 slight improvement and 
in 1 there was no improvement. These 
findings show that the response to Doxepin 
was satisfactory taking into consideration 
that all the patients had moderate to severe 
depression, with a mean score of 35.33 in 
group D and 32.76 in group N. 
There was no attempt to make the two 
sexes equal in the sampling. However, 
the higher number of females in the total 
sample could be explained due to a high 
mental illness morbidity among females 
in our centre, which also holds true for 
depressive illness. 
The second aim of the study was to 
compare the efficacy and tolerability of the 
drug when given in divided doses during 
the day and as a single nocturnal dose. 
Once a day dosage schedule has the ad-
vantage that it is more likely to be taken 
than divided doses (General Practitioner 
Research Group 1970 : Porter, 1969) parti-
cularly since depressed patients seldom keep 
to prescribed drug schedules. (Wilcox et 
al., 1965). 
A similar study carried out by Pearce 
and Rees (1974) showed that more favour-
able results were achieved with patients 
taking the single nocturnal dose of Dothiepin 
which was well tolerated in addition to 
being effective in relieving the symptoms 
of depression. However we have observed 
that both the dosage regimens are equally 
effective in relieving the symptoms of 
depression and the side-effects were mild 
in both the groups but incicence of side 
effects like palpitation, nausea, vomiting 
and blurred vision were not observed in 
group N. This finding is not surprising 
in view of the half lives of tricyclic com-
pounds in general and the fact that attain-
ment of a steady concentration is reached 
when the patient is sleeping, thus avoiding 
the mild subjective distress. 
Body weight 
A moderate increase in body weight 
with Doxepin was similar to weight-gain 
seen with other antidepressants. This weight 
gain was usually small but in some cases 
it was quite large (above 3 kg. in 4 patients). 
Various reasons have been ascribed in the 
literature for this gain in weight. 
Target symptoms 
Clinically the target symptoms which 
responded best to Doxepin were agitation, 
depression and anxiety. 
It was observed that the divided and 
single dosage regimens did not cause any 
differences in therapeutic effectiveness. Si-
milarly there was no significant difference 
in the incidence of side-effects. The p-esent 
study suggests that the single nocturnal 
dosage of doxepin is well tolerated and is 
as effective as the thrice daily dosage 
schedule. 
Haematological and biochemical studies 
did not reveal any significant changes in 
both the groups. 
CONCLUSION 
Doxepin, the new tricyclic antidepres-
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with moderately severe depression. It was 
observed that the divided and single dosage 
regimens did not cause any difference in 
therapeutic effectiveness. Similarly there 
was no significant difference in the incidence 
of side-effects (P>.05). 
Since the introduction of the drug in 
the management of depression, thrice daily 
dose is so fa- generally recommended but 
the present study indicates that the thera-
peutic effects are as satisfactory with single 
nocturnal doses with the added advantage 
of better tolerance. It thus offers the choice 
of flexibility in the management of depres-
sion with the nocturnal therapy offering 
an additional advantage of patient's com-
pliance and convenience. Though we do 
not have enough data to offer a firm con-
clusion, it is suggested that single dose 
therapy may be avoided in the geriatric 
population, till more data are available. 
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